New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOvagen vs Tirzepatide

Ovagen vs Tirzepatide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Ovagen
GLP-1 / Weight Loss Agonists
Tirzepatide
Summary
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Half-Life
Short (minutes); sustained gene-regulatory effects
~5 days
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Frequency
Daily for 10–30 days
Once weekly, subcutaneous
Key Benefits
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
  • Average 21% body weight reduction at highest dose (SURMOUNT-1)
  • Superior to semaglutide in head-to-head SURPASS trials
  • Dual GIP/GLP-1 mechanism for enhanced metabolic control
  • Significant reduction in HbA1c for type 2 diabetes
  • Improved cardiovascular risk markers
  • Reduces visceral fat preferentially
  • FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
  • Weekly dosing
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • +3 more
Stacks With